Morgan Stanley’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Morgan Stanley’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,418	Closed	-$144K	–	7858
2023 Q2	$144K	Sell	6,418 -12,569	-66%	-$91.2K	﹤0.01%	5787
2023 Q1	$230K	Buy	18,987 +16,668	+719%	+$173K	﹤0.01%	5650
2022 Q4	$10.6K	Buy	2,319 +61	+3%	+$348	﹤0.01%	6914
2022 Q3	$15K	Sell	2,258 -969	-30%	-$8.85K	﹤0.01%	6937
2022 Q2	$35K	Sell	3,227 -1,078	-25%	-$14.5K	﹤0.01%	6780
2022 Q1	$82K	Sell	4,305 -26,156	-86%	-$583K	﹤0.01%	6449
2021 Q4	$1.09M	Sell	30,461 -8,486	-22%	-$483K	﹤0.01%	5008
2021 Q3	$2.86M	Sell	38,947 -3,125	-7%	-$240K	﹤0.01%	4276
2021 Q2	$5.87M	Buy	42,072 +41,916	+26,869%	+$7.36M	﹤0.01%	3619
2021 Q1	$45K	Sell	156 -93	-37%	-$37K	﹤0.01%	6398
2020 Q4	$155K	Buy	+249	New	+$113K	﹤0.01%	5721

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's SGTX Position: Q3 2023 in Review

Morgan Stanley sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 6,418 shares — an estimated $144K sold.

Morgan Stanley first reported a position in SGTX in Q4 2020 and held it in 11 quarters. The position peaked at $5.87M in Q2 2021. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

Morgan Stanley reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 6,418 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $144K.
Morgan Stanley first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Morgan Stanley's Sigilon Therapeutics, Inc. Common Stock position peaked at $5.87M in Q2 2021.
1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.